For the world at large these figures are worse, with less than 10% of patients on multidrug treatment in low-and middle-income countries. 3 The benefits of cardiac rehabilitation programmes following a myocardial infarction have been well demonstrated. Yet, the participation in cardiac rehabilitation programmes shows similar limitations, with less than half patients regularly attending exercise programmes.
4,5

Implementation
We know what is needed, but we need to know better how to achieve our goals. Guidelines have become monumental demonstrations of advancements in evidence-based medicine. 4, 6 Lengthy documents provide detailed and refined recommendations for diagnosis and treatment of high-risk individuals. There is, however, a gap between these bodies of knowledge and their translation in everyday care. First and foremost, awareness is needed about the nature of cardiovascular disease and its risk factors, behavioural risks and the way these risks can be reduced by changes in lifestyle and medication; awareness on an individual level, but also awareness with governments and health care professionals. People tend to underestimate long-term risks and prevention gives few immediate incentives. In high-risk individuals, multiple drugs are needed but the prescription of multiple drugs and doses every day for a long period is reducing compliance. For each additional drug, compliance will fall by 5-10%. 7 Understanding the need for compliance, monitoring drug use and explanation of the need for appropriate use of prescribed medications require the attention of physicians and careful communication. Strategies may need to be adjusted according to level of education, social economic and cultural and ethnic differences. Multiple studies have now demonstrated that fixed dose combinations, or polypills, promote compliance and improve risk factor controls, but these compounds have only recently entered the market and are not yet part of the routine arsenal of drug strategies in highrisk patients with low compliance. 8 
Innovations
True breakthroughs in drug innovation or other strategies are few and far between. A group at particularly high risk is patients with diabetes and cardiovascular disease. 9 So far, the macrovascular benefits of rigorous glucose lowering to HbA1C levels below 7 mmol/l have not been demonstrated. 10 However, first results with some newer drugs such as Sodium/Glucose Cotransporter 2 (SGLT2) inhibitors show promising results. 11 There is good evidence that lipid lowering and blood pressure reduction in diabetic patients, even with cholesterol in the normal range and without clear hypertension, will reduce the risk of subsequent cardiovascular events. 12 Probably the best way to reduce risk in diabetes is normalization of body weight. However, sustained weight loss is difficult to achieve. 13 Overall, obesity rates in Europe, as in many other parts of the world, show steady increases, heralding an epidemic of cardiovascular disease that risks negating the progress made in disease prevention and treatment over the last decades.
14 There are few new, and more effective or safe, strategies for treatment of hypertension and smoking cessation. There are, however, new drugs to further lower serum lipid levels on top of existing strategies including statin treatment. The first of new classes of drugs now approved for use in clinical care are so-called Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) inhibitors: monoclonal antibodies that are injected at regular intervals of a couple of weeks and that reduce LDL levels spectacularly in most patients. Very recently the first results on clinical outcomes in secondary prevention by use of PCSK9 inhibitors on top of full statin treatment have shown significant improvements in cardiovascular prognosis. 15 A major limitation of the use of this class of drugs is currently the high cost associated with its use. Consequently, reimbursements are likely to remain restricted to statin intolerant patients and patients with severe familial hypercholesterolaemia. For cardiovascular rehabilitation, innovations may be particularly found in alternative modes of provision and monitoring such as through tele-monitoring and on-line programmes. 16 Early trials have shown that these approaches may be equally effective, more scalable and well accepted by patients. In a more general sense, the data-revolution and e-medicine may change the way prevention is provided and implemented. Already a large proportion of patients are using smart phones which may be equipped with apps suggesting risk reducing strategies and helping to improve compliance with lifestyle measures and drugs. Physicians may use streaming data or queries through apps to follow patients' behaviours and risks.
Conclusion
In summary, there is an abundance of data on optimal approaches to prevent subsequent events in patients with cardiovascular disease. The implementation of this knowledge to effective individual preventive strategies in real life, however, requires more attention. Currently, large proportions of high-risk individuals in Europe and the rest of the world are not sufficiently protected and may even not be aware of the risk they run. This issue of the European Journal of Preventive Cardiology presents a series of papers addressing a number of important aspects of secondary prevention. They form part of the second phase of the Secondary Prevention Programme run by the European Association of Preventive Cardiology in collaboration with the European Society of Cardiology Council on Cardiovascular Nursing and Allied Professionals and the Acute Cardiac Care Association (Table 1) . This second phase specifically addresses health professionals in Europe and beyond. The third phase is planned to commence early in 2018 and will focus more strongly on patients. Part of the third phase will be language specific websites with information and advice directed to patients as well as support of European patient involvement and shared decision making. Finally, the European Association for Preventive Cardiology plans 
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